Pancreatic Cancer Research

ResearcherThe Royal Free HospitalActive in the last 2 years

Peter Lawrence Zaki Labib

Matched on ORCID iD 0000-0003-2362-9218; OpenAlex author ID A5054515294. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 3 papers

Papers 9

  1. Intention to treat outcomes following management of locally advanced pancreatic ductal adenocarcinoma with curative intent: single centre cohort study. Co-author DOI 10.1016/j.hpb.2026.06.008↗
  2. Temporary Mesocaval Shunt: A Surgical Strategy to Facilitate Pancreatic Cancer Resection With Complex Vascular Involvement. Co-author DOI 10.1111/ans.70977↗
  3. Intranetwork variation in neoadjuvant therapy delivery for borderline resectable and locally advanced pancreatic cancer: a UK multicentre cohort study. Co-author DOI 10.1308/rcsann.2026.0023↗
  4. Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospectiv… Co-author DOI 10.1016/j.hpb.2024.11.015↗
  5. Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma-A Multicentre Propensity Score Matching Analysis of the Recurrence After Whi… Co-author DOI 10.3390/cancers17071223↗
  6. Five-year recurrence/survival after pancreatoduodenectomy for pancreatic adenocarcinoma: does pre-existing diabetes matter? Results from the Recurrence After W… Co-author DOI 10.1016/j.hpb.2024.04.010↗
  7. Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentr… First author DOI 10.14701/ahbps.23-042↗
  8. 5-Aminolevulinic acid for fluorescence-guided surgery in pancreatic cancer: Cellular transport and fluorescence quantification studies. Co-author DOI 10.1016/j.tranon.2020.100886↗
  9. Timing of administration of indocyanine green for fluorescence-guided surgery in pancreatic cancer: response to Shirakawa et al. Co-author DOI 10.1186/s12893-020-00881-x↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith John Roberts · 4 shared papers, 2023–2026 · strength 0.80
  2. Nikolaos A. Chatzizacharias · 3 shared papers, 2026 · strength 0.69
  3. Sarah F. Powell-Brett · 3 shared papers, 2026 · strength 0.69
  4. Moath Alarabiyat · 3 shared papers, 2026 · strength 0.69
  5. David Christopher Bartlett · 2 shared papers, 2026 · strength 0.46
  6. Robert Peter Sutcliffe · 2 shared papers, 2026 · strength 0.46
  7. S.S. Raza · 2 shared papers, 2026 · strength 0.46
  8. Brian Ritchie Davidson · 3 shared papers, 2021–2025 · strength 0.45
  9. James S. Good · 2 shared papers, 2026 · strength 0.41
  10. Lewis A Hall · 2 shared papers, 2026 · strength 0.41
  11. Shivan Sivakumar · 2 shared papers, 2026 · strength 0.41
  12. Duncan R.C. Spalding · 2 shared papers, 2023–2025 · strength 0.28
  13. Alberto Porcu · 2 shared papers, 2023–2025 · strength 0.28
  14. Thomas Brendon Russell · 2 shared papers, 2023–2025 · strength 0.28
  15. Fabio Ausania · 2 shared papers, 2023–2025 · strength 0.28
  16. Ricky Harminder Bhogal · 2 shared papers, 2023–2025 · strength 0.28
  17. Somaiah Aroori · 2 shared papers, 2023–2025 · strength 0.28
  18. Ismael Domínguez-Rosado · 2 shared papers, 2023–2025 · strength 0.28
  19. Dhanny Gomez · 2 shared papers, 2023–2025 · strength 0.28
  20. Manuel Maglione · 2 shared papers, 2023–2025 · strength 0.28
  21. Andrew Malvern Smith · 2 shared papers, 2023–2025 · strength 0.28
  22. Zaed Z. R. Hamady · 2 shared papers, 2023–2025 · strength 0.28
  23. Daniel Gerald Croagh · 2 shared papers, 2023–2025 · strength 0.28
  24. Elizabeth Pando Rau · 2 shared papers, 2023–2025 · strength 0.28
  25. Adam Enver Frampton · 2 shared papers, 2023–2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.